The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

76 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.EBI
University Of Minnesota
Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.EBI
Genomics Institute Of Novartis Research Foundation
Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives.EBI
Glaxosmithkline
Dihydropyrrolo[2,3-d]pyrimidines: Selective Toll-Like Receptor 9 Antagonists from Scaffold Morphing Efforts.EBI
Sumitomo Dainippon Pharma
Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.EBI
Dainippon Sumitomo Pharma
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.EBI
TBA
Medicinal chemistry approaches to avoid aldehyde oxidase metabolism.EBI
Pfizer
Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.EBI
University Of Kansas
Discovery of a highly potent series of TLR7 agonists.EBI
Pfizer
Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.EBI
University Of Kansas
Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines.EBI
University Of Kansas
Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.EBI
Pfizer
Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7.EBI
University Of Kansas
Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues.EBI
University Of Kansas
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.EBI
Dainippon Sumitomo Pharma
Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline.EBI
University Of Kansas
Small molecule modulators of toll-like receptors.EBI
Schering-Plough Research Institute
Novel Triazatricycle Compounds for Treating Autoimmune Diseases.EBI
Smith, Gambrell & Russell
Novel Carbazoles for Treating Inflammatory and Autoimmune Diseases.EBI
Smith, Gambrell & Russell
Synthesis and characterization of new potent TLR7 antagonists based on analysis of the binding mode using biomolecular simulations.EBI
Csir-Indian Institute Of Chemical Biology
Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles.EBI
University Of Kansas
Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.EBI
Genomics Institute Of The Novartis Research Foundation
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.EBI
Gilead Sciences
Novel Hexahydro-1EBI
Smith, Gambrell & Russell
Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival.EBI
Astrazeneca
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.EBI
University Of Montana
Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).EBI
Princ
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.EBI
Genomics Institute Of The Novartis Research Foundation
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.EBI
University Of Kansas
A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist.EBI
Csir-Indian Institute Of Chemical Biology
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[EBI
Glaxosmithkline
Novel and Selective TLR7 Antagonists among the Imidazo[1,2-EBI
Universit£
Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors EBI
University Of Colorado Boulder
Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds.EBI
University Of Ljubljana
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.EBI
University Of Minnesota
NLRP3 Modulators for the Treatment of Autoinflammatory Disorders.EBI
Usona Institute
Activity-guided development of potent and selective toll-like receptor 9 antagonists.EBI
Csir-Indian Institute Of Chemical Biology
Toll-like Receptors for the Treatment of Autoimmune, Inflammation, and Infectious Diseases.EBI
Usona Institute
Discovery of Novel Small-Molecule Inhibitors of NF-?B Signaling with Antiinflammatory and Anticancer Properties.EBI
University Of Colorado
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.EBI
University Of Minnesota
Design and development of benzoxazole derivatives with toll-like receptor 9 antagonism.EBI
Csir-Indian Institute Of Chemical Biology
Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.EBI
Janssen Pharmaceutica
Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.EBI
University Of Colorado Boulder
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.BDB
Yale University
Structural and thermodynamic analyses of α-L-fucosidase inhibitors.BDB
University Of York
Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in-vivo alpha 1-,alpha 2- and 5-HT2-receptor antagonism and in-vitro affinity for alpha 1-,alpha 2- and 5-HT2-receptors: comparison with ketanserin.BDB
TBA
Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors.BDB
TBA
Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.BDB
Purdue University
Inhibition of adenosine deaminase by analogues of adenosine and inosine, incorporating a common heterocyclic base, 4(7)-amino-6(5)H-imidazo[4,5-d]pyridazin-7(4)one.BDB
University Of Maryland Baltimore County
Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 2: structure-activity relationship studies on the benzopyran scaffold.BDB
Eli Lilly
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.BDB
Eli Lilly
Structure-based design of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1).BDB
Pfizer
Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes.BDB
University Of Dundee
Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation.BDB
University Of Bologna
Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.BDB
Bristol-Myers Squibb